摘要
目的比较三种同步放化疗方案治疗局部晚期非小细胞肺癌的成本-效果。方法 65例局部晚期非小细胞肺癌患者,按不同化疗方案(EP、TC及NP)与三维适形放疗同步治疗,回顾性评价各组成本-效果。结果三种同步放化疗方案有效率分别为:67.74%(21例/31例,TC组)、65.00%(13例/20例,NP组)和50.00%(7例/14例,EP组),TC组及NP组有效率高于EP组,统计学差异显著(P<0.05);三组费用成本分别为23559.59元(TC组)、20184.84元(NP组)和18863.44元(EP组),成本-效果比分别是347.79、310.54和377.27;相对于EP组,TC、NP组的增量成本-效果比分别是264.72和88.09。结论成本-效果分析提示,在评价的三种同步放化疗方案中NP联合同步三维适形放疗方案最具优势。
Objective To observe the cost-efficacy of three kinds of therapy programs for local advanced non-small cell lung cancer. Methods Sixty-five patients with local advanced non-small cell lung cancer were divided into three groups（TC, NP and EP group） based on different treatments of concurrent chemotherapy and radiotherapy. The costefficacy was evaluated retrospectively. Results The effective rates of three groups were 67.74%（21/31, TC）, 65.00% （13/20, NP）and 50.00%（7/14, EP）. The rates of group TC and NP were higher than that of group EP signifi cantly. The costs of three groups were 23 559.59（TC）, 20 184.84（NP） and 18 863.44（EP）yuan. The cost-efficacy of three groups were 347.79, 310.54 and 377.27. Compared with group EP, the increased cost-efficacy of group TP and NP were 264.72 and 88.09, respectively. Conclusion The NP program has the best cost-efficacy among the three programs.
出处
《世界临床药物》
CAS
2010年第10期603-607,共5页
World Clinical Drug
基金
上海市卫生局研究基金--局部晚期非小细胞肺癌同步放化疗的卫生经济学分析(编号:2008035)
关键词
同步化疗
放疗
非小细胞肺癌
成本-效果分析
药物经济学
concurrent chemotherapy
radiotherapy
non-small cell lung cancer
cost-efficacy analysis
pharmacoeconomics
